Anti-Vascular Endothelial Growth Factor Treatment Compared with Steroid Treatment for Retinal Vein Occlusion: A Meta-Analysis release_kpmxmgiaybb2hdinjqvlvbjzgm

by Nikhil S. Patil, Amin Hatamnejad, Andrew Mihalache, Marko Popovic, Peter Kertes, Rajeev H. Muni

Published in Ophthalmologica by S. Karger AG.

2022   Volume 245, Issue 6, p500-515

Abstract

<b><i>Background:</i></b> Intravitreal anti-vascular endothelial growth factor (anti-VEGF) and steroid treatment are both used for macular edema (ME) secondary to retinal vein occlusion (RVO), however a continual reevaluation of their comparative efficacy is required. <b><i>Objectives:</i></b> This meta-analysis aimed to compare the efficacy and safety of intravitreal anti-VEGF agents and intravitreal steroids for the treatment of ME secondary to RVO. <b><i>Methods:</i></b> A systematic literature search was conducted on Ovid MEDLINE, EMBASE, and the Cochrane Controlled Register of Trials for studies published between January 2005 and November 2021. Randomized controlled trials (RCTs) reporting on patients with ME secondary to RVO who were treated with intravitreal steroids or anti-VEGF agents were included. A random effects meta-analysis was performed. <b><i>Results:</i></b> 879 eyes from 11 RCTs were included. At the last study observation, intravitreal anti-VEGF agents were associated with a significantly better best corrected visual acuity (WMD = −0.14 logMAR, 95% CI = [−0.19, −0.09], <i>p</i> < 0.00001) and lower retinal thickness (WMD = −38.01 µm, 95% CI = [−56.17, −19.85], <i>p</i> < 0.0001) relative to intravitreal steroids. Similar findings were found at 3–12 month time points. Intravitreal anti-VEGF agents were associated with a significantly lower incidence of IOP-related adverse events (RR = 0.28, 95% CI = [0.15, 0.51], <i>p</i> < 0.0001), cataract development/progression (RR = 0.22, 95% CI = [0.09, 0.49], <i>p</i> = 0.0003), and conjunctival hemorrhage (RR = 0.52, 95% CI = [0.32, 0.86], <i>p</i> = 0.01). <b><i>Conclusions:</i></b> Our meta-analysis found superiority of intravitreal anti-VEGF agents relative to intravitreal steroids for the treatment of ME secondary to RVO with regards to visual acuity, anatomic outcomes, and safety endpoints.
In application/xml+jats format

Archived Files and Locations

application/pdf   2.8 MB
file_binttj3fjbd6tjrzc77tle5pj4
www.karger.com (publisher)
web.archive.org (webarchive)
Read Archived PDF
Preserved and Accessible
Type  article-journal
Stage   published
Date   2022-11-16
Language   en ?
DOI  10.1159/000527626
PubMed  36288721
Container Metadata
Not in DOAJ
In Keepers Registry
ISSN-L:  0030-3755
Work Entity
access all versions, variants, and formats of this works (eg, pre-prints)
Catalog Record
Revision: 034f1087-2aad-4dac-99af-953eb7a2e1b9
API URL: JSON